Literature DB >> 2190630

Clinical and pharmacological study of a novel controlled release preparation of salbutamol.

R Milroy1, R Carter, D Carlyle, G Boyd.   

Abstract

This study compared the efficacy of 8 mg controlled release (CR) salbutamol tablets twice daily with standard 4 mg salbutamol tablets four times daily in patients with chronic obstructive airways disease. There was significant bronchodilation in both treatment groups as measured by standard spirometry (P less than 0.05). With the CR preparation there was significantly less wheeze (P less than 0.05) and significantly reduced requirement for rescue bronchodilator (P less than 0.05). Salbutamol levels measured hourly on the final day of each treatment period showed that the drug profile in the CR group was smoother, without the troughs and peaks seen with standard tablets.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190630      PMCID: PMC1380159          DOI: 10.1111/j.1365-2125.1990.tb03683.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease.

Authors:  F P Maesen; J J Smeets
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  New directions in asthma: some cause for concern.

Authors:  A Abbott
Journal:  Trends Pharmacol Sci       Date:  1988-05       Impact factor: 14.819

4.  Evolution and design of 'rate controlled' osmotic forms.

Authors:  F Theeuwes
Journal:  Curr Med Res Opin       Date:  1983       Impact factor: 2.580

  4 in total
  2 in total

1.  Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.